U.S. Markets closed

Lipocine Inc. (LPCN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.71+0.08 (+1.73%)
At close: 4:00PM EDT
People also watch
MRNSSCYXEVOKTNXPTRIL
Full screen
Previous Close4.63
Open4.58
Bid4.60 x 200
Ask5.19 x 500
Day's Range4.58 - 4.72
52 Week Range3.03 - 5.90
Volume209,488
Avg. Volume421,806
Market Cap90.72M
Beta1.98
PE Ratio (TTM)-5.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research2 months ago

    LPCN 1021 Readout in June; 1Q:17 R&D Costs Lower

    By John Vandermosten, CFA NASDAQ:LPCN 1Q:17 Operational and Financial Results On May 9th Lipocine Inc. (NASDAQ:LPCN) filed its first quarter 2017 10-Q in conjunction with a press release highlighting recent ...

  • Associated Press2 months ago

    Lipocine reports 1Q loss

    The Salt Lake City-based company said it had a loss of 26 cents per share. The company's shares closed at $4.15. A year ago, they were trading at $8.91. _____ This story was generated by Automated Insights ...

  • Zacks Small Cap Research4 months ago

    LPCN: Conserving Cash to Fund Underway DV and DF Studies

    On March 6th Lipocine Inc. (LPCN) filed its 2016 10-K in conjunction with a press release highlighting 2016 achievements.  For the year, Lipocine reported a net loss of $19 million and $1.04 per share which compares to our estimates of $20.4 million and $1.10 per share.  Lower R&D and lower SG&A both contributed to the difference.  We were under the impression that the trial costs related to the dosing validation (DV) study which began in December would cause a sequential jump in R&D expenses rather than a decline.